Iovance Biotherapeutics, Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Iovance Biotherapeutics, Inc. listata cu simbolul US.IOVA ==Descriere companie== Iovance Biotherapeutics, Inc. (http://www.iovance.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumo...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Iovance Biotherapeutics, Inc. (http://www.iovance.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. The Company’s lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, the Company is investigating the effectiveness and safety of TIL therapy and peripheral blood lymphocyte (PBL) therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer (NSCLC), and chronic lymphocytic leukemia (CLL). | Iovance Biotherapeutics, Inc. (http://www.iovance.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. The Company’s lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, the Company is investigating the effectiveness and safety of TIL therapy and peripheral blood lymphocyte (PBL) therapy for the treatment of squamous cell carcinoma of the [[head]] and neck, non-small cell lung cancer (NSCLC), and chronic lymphocytic leukemia (CLL). | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 1 octombrie 2024 14:49
Pagina dedicata companiei Iovance Biotherapeutics, Inc. listata cu simbolul US.IOVA
Descriere companie[edit | ]
Iovance Biotherapeutics, Inc. (http://www.iovance.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. The Company’s lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, the Company is investigating the effectiveness and safety of TIL therapy and peripheral blood lymphocyte (PBL) therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer (NSCLC), and chronic lymphocytic leukemia (CLL).
Grafic actiuni companie[edit | ]